Hong Zhang, M.D., Ph.D.

Contact Information

Phone Numbers

Appointment: (585) 341-6750

Office: (585) 341-6750

Fax: (585) 275-1531

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Biography

It is a privilege to care for our patients. I am committed to providing personalized radiation treatment of the highest quality, as well as compassionate care. My areas of expertise include prostate and head and neck cancers.

Conditions I Treat:

- Prostate cancer
- Head and neck cancers
- Breast cancer
- Other cancers

Credentials

Specialties

Radiation Oncology - American Board of Radiology

Education

1993
PHD | Case Western Reserve University School of Medicine

2001
MD | Yale University

Post-doctoral Training & Residency

07/01/2002 - 06/30/2006
Residency in Radiation Oncology at University of Rochester Medical Center

06/01/2001 - 06/01/2002
Internship in Internal Medicine at Rochester General Hospital

06/01/1993 - 12/31/1994
Fellowship at Case Western Reserve University Endodontics Residency

VIEW ALL

Awards

2018
Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester

2017
AAMC Mid-Career Woman Faculty Leadership Development Seminar 12/2017
Sponsor: AAMC

2017
Health Care Achievement Awards--Health Care Innovation
Sponsor: Rochester Business Journal
Location: Rochester, NY

2016
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2013
Patient- and Family- Centered ICARE High Performance Award

2012 - 2017
Civic Service Award, Us TOO Rochester
Sponsor: Us TOO Rochester

2012
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2012
Patient- and Family-Centered ICARE High Performance Award
Sponsor: University of Rochester Medical Center

2005
Upstate New York Society of Therapeutic Radiology and Oncology Fall Meeting Resident Presenter Award
Location: Syracuse, NY

2005
ASTRO Translational Research in Radiation Oncology Symposium Travel Grant Award

2001
Janet M.Glasgow Memorial Achievement Citations
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut

2000
Clyde Swift Award for Outstanding Medical Student
Sponsor: Yale University School of Medicine
Location: New Haven, Connecticut

VIEW ALL

Clinical Trials

A Pilot Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

Lead Researcher: Hong Zhang

The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.

View Study Details

Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy,Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy

Lead Researcher: Hong Zhang

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

View Study Details

Publications

Journal Articles

2022
Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; et al. "Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer". Radiother Oncol. 2022; 168: 75-82.

2022
Zhang H; Yang H; Bandyopadhyay S; Milano MT; Fung C; Messing EM; Chen Y. "Increased risk of high-grade prostate cancer among testicular cancer survivors". PLoS One. 2022; 17(2): e0263573.

5/2021
Zhang H, Yu A, Baran A, Messing E. "Risk of second cancer among young prostate cancer survivors." . 2021 May; 39(2):91-98. Epub 2021 Jun 28.

Books & Chapters

2009
Chapter Title: Breast Cancer
Book Title: Principles and Practice of Radiation Therapy
Author List: Uschold G; Zhang H
Edited By: Washington CM; Leaver D
Published By: Mosby Elsevier 2009

VIEW ALL PUBLICATIONS